PRAX Receives FDA Breakthrough
Praxis Precision Medicines receives FDA Breakthrough Therapy Designation for Elsunersen to treat seizures associated with SCN2A developmental and epileptic encephalopathy
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.